Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

AIMS The principal aim of the second EUROASPIRE survey was to determine in patients with established coronary heart disease whether the Joint European Societies' recommendations on coronary prevention are being followed in clinical practice. METHODS This survey was undertaken in 1999-2000 in 15 European countries: Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Poland, Slovenia, Sweden, Spain and the U.K., in selected geographical areas and 47 centres. Consecutive patients, men and women < or =70 years were identified retrospectively with the following diagnoses: coronary artery bypass graft, percutaneous transluminal coronary angioplasty, acute myocardial infarction and myocardial ischaemia. Data collection was based on a review of medical records and interview and risk assessment at least 6 months after hospital admission. RESULTS 8181 medical records (25% women) were reviewed and 5556 patients (adjusted participation rate 76%) interviewed. Recording of risk factor history and risk factor measurement in hospital notes was incomplete, particularly for discharge documents. At interview (median time 1.4 years after hospital discharge), 21% of patients smoked cigarettes, 31% were obese, 50% had raised blood pressure (systolic blood pressure > or =140 mmHg and/or diastolic blood pressure > or =90 mmHg), 58% had elevated serum total cholesterol (total cholesterol > or =5 mmol x l(-1)) and 20% reported a medical history of diabetes. Glucose control in these diabetic patients was poor with 87% having plasma glucose >6.0 mmol x l(-1)and 72% > or =7.0 mmol x l(-1). Among the patients interviewed the use of prophylactic drug therapies on admission, at discharge and at interview was as follows: aspirin or other antiplatelets drugs 47%, 90% and 86%; beta-blockers 44%, 66% and 63%; ACE inhibitors 24%, 38% and 38%; and lipid-lowering drugs 26%, 43% and 61%, respectively. With the exception of antiplatelet drugs, wide variations in the use of prophylactic drug therapies exist between countries. CONCLUSIONS This European survey of coronary patients shows a high prevalence of unhealthy lifestyles, modifiable risk factors and inadequate use of drug therapies to achieve blood pressure and lipid goals. There is considerable potential throughout Europe to raise the standard of preventive cardiology through more effective lifestyle intervention, control of other risk factors and optimal use of prophylactic drug therapies in order to reduce coronary morbidity and mortality.

[1]  A. Dans,et al.  Prevalence of hypertension in CHD patients in the asia-pacific region: the aspac study , 2000 .

[2]  A. Keech,et al.  Prevalence of smoking among CHD patients in the asia-pacific: the ASPAC study , 2000 .

[3]  A. Keech,et al.  Hypercholesterolaemia as a risk factor for coronary heart disease in the Asia-Pacific region: The ASPAC study , 2000 .

[4]  Michael C. Fiore,et al.  A Clinical Practice Guideline for Treating Tobacco Use and Dependence A US Public Health Service Report , 2000 .

[5]  P. Amouyel,et al.  Overweight and obesity: a major challenge for coronary heart disease secondary prevention in clinical practice in Europe. , 2000, European heart journal.

[6]  K. Fagerström,et al.  Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. , 2000, European heart journal.

[7]  A. Dobson,et al.  Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations , 2000, The Lancet.

[8]  W. Koenig,et al.  The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? , 2000, Diabetologia.

[9]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[10]  N. Benowitz,et al.  Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy , 2000 .

[11]  Sonia S Anand,et al.  Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.

[12]  M. Simoons,et al.  Impact of smoking cessation and smoking interventions in patients with coronary heart disease. , 1999, European heart journal.

[13]  J. Feely,et al.  The therapeutic gap--compliance with medication and guidelines. , 1999, Atherosclerosis.

[14]  K. Tragl,et al.  [Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria]. , 1999, Wiener klinische Wochenschrift.

[15]  1999 European Diabetes Policy Group A desktop guide to Type 2 diabetes mellitus , 1999 .

[16]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[17]  A. Majeed,et al.  Management of ischaemic heart disease in primary care: towards better practice. STaRNet. South Thames Region Network. , 1999, Journal of public health medicine.

[18]  H. Tunstall-Pedoe,et al.  Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations , 1999, The Lancet.

[19]  Sidney C. Smith,et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[20]  M. Armitage,et al.  Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. , 1999, QJM : monthly journal of the Association of Physicians.

[21]  M. Pfeffer,et al.  Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. , 1999, Journal of the American College of Cardiology.

[22]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[23]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[24]  Ian Graham,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[25]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[26]  R L Brown,et al.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. , 1998, Archives of internal medicine.

[27]  N. Campbell,et al.  Secondary prevention clinics for coronary heart disease: randomised trial of effect on health , 1998, BMJ.

[28]  V. Salomaa,et al.  Impact of Diabetes on Mortality After the First Myocardial Infarction , 1998, Diabetes Care.

[29]  F. Gutzwiller,et al.  International Comparison of Awareness and Attitudes Towards Coronary Risk Factor Reduction: The HELP Study , 1997, Atherosclerosis.

[30]  P. Währborg,et al.  Risk indicators for recurrence among patients with coronary artery disease. Problems associated with their modification. , 1998, Scandinavian cardiovascular journal : SCJ.

[31]  G. Parati,et al.  Early and late sympathetic activation in hypertension. , 1998, Scandinavian cardiovascular journal. Supplement.

[32]  T. Pearson,et al.  The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. , 1997, The American journal of cardiology.

[33]  J. Boer,et al.  Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. , 1997, Circulation.

[34]  D Kromhout,et al.  The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. , 1997, European heart journal.

[35]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[36]  J. Carrasco,et al.  La prevención secundaria del infarto de miocardio en España. Estudio PREVESE , 1997 .

[37]  M. Dennis A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[38]  K. Pyörälä CHD prevention in clinical practice , 1996, The Lancet.

[39]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[40]  J Herlitz,et al.  Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. , 1996, European heart journal.

[41]  T. Bowker,et al.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.

[42]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[43]  J. Cutler,et al.  Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .

[44]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[45]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .